British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

Ziresovir earns global recognition, boosting hope for young RSV patients and strengthening ArkBio’s innovative pipeline.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

In the newly released 'Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report' by Global ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...